Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Acceleron Pharma Inc. maintains a patent portfolio with 9 pending office actions at the patent office, primarily focused within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 8 distinct examiners, suggesting a distribution of examination styles and preferences. The portfolio also spans 5 distinct art units, which reflects the range of technical subject matter being prosecuted simultaneously.
BERHANE, SELAM is identified as the busiest examiner for the company, currently overseeing 2 pending office actions. While this official holds the highest individual count, the total of 9 pending actions indicates that no individual dominates the company's legal strategy. Practitioners should prepare for varied feedback across the 5 distinct art units involved. The distribution of work across the portfolio demonstrates that the prosecution is not heavily bottlenecked by any one individual, despite BERHANE, SELAM managing 2 of those cases at this time.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (22%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 2 | 58.4% | +56.7% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| MIKNIS, ZACHARY J | 1 | 68.6% | +32.2% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010888 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HOWARD, ZACHARY C | 26d |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 70d |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | MIKNIS, ZACHARY J | 21d |
| 18010888 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HOWARD, ZACHARY C | 26d |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 70d |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | — |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | — |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| 18549474 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1654 | 1 |
| 1641 | 1 |
| 1658 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — | DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | — | §102§103DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | — | §112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18549474 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | BERHANE, SELAM | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18549461 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HADDAD, MAHER M | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | BERHANE, SELAM | 1675 | §103§112 | Non-Final OA | 70d | Pending | Jun 02, 2023 |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | MIKNIS, ZACHARY J | 1658 | §112 | Non-Final OA | 21d | Pending | Dec 19, 2022 |
| 18010888 | ACTRII-ALK4 ANTAGONISTS AND METHODS OF TREATING HEART FAILURE | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 26d | Pending | Dec 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial